NYSE - Nasdaq Real Time Price USD

Merck & Co., Inc. (MRK)

129.65

+2.65

(+2.09%)

As of 10:28 AM EDT. Market Open.

Meta, IBM sink on earnings, American Airlines and Caterpillar report: Yahoo Finance

Meta, IBM sink on earnings, American Airlines and Caterpillar report: Yahoo FinanceShares of Meta (META) are deep in the red this morning despite the company beating earnings expectations. Investors were spooked by the tech giant’s second-quarter outlook. IBM (IBM) shares are also falling this morning after reporting first-quarter revenue that missed expectations. Today we will hear from several top names, including American Airlines (AAL), Caterpillar (CAT), Merck (MRK), Royal Caribbean (RCL), Microsoft (MSFT), Alphabet (GOOGL, GOOG), Intel (INTC), and Roku (ROKU). Yahoo Finance trending tickers include Chipotle (CMG), ServiceNow (NOW), and Ford (F). Key guests include: 9:30 a.m. ET - Ryan Detrick, Carson Group Chief Market Strategist 9:45 a.m. ET - Jack Hartung, Chipotle CFO 10 a.m. ET - Roger McNamee, Elevation Partners Co-Founder 10:10 a.m ET - Glenn Kelman, Redfin CEO 11 a.m. ET - Glenn Kelman, Redfin CEO

Yahoo Finance Video 2 hours ago

AAL

IBM

NOW
Alphabet, Microsoft, Southwest earnings: What to watch

Here are some of the biggest stories investors will be watching on Thursday, April 25, 2024. A slew of companies will report their quarterly results including Microsoft (MSFT), Alphabet (GOOG, GOOGL), and Southwest Airlines (LUV). On the economic data front, the highly anticipated preliminary read on first quarter GDP will be released. Economists are expecting that the US economy grew by 2.2% in the first three months of the year. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith

Yahoo Finance Video 16 hours ago

CMCSA

TMUS

CAT
We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

Simply Wall St. 1 hour ago

MRK
+2.09%
UPDATE 1-Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda

Merck & Co on Thursday raised its annual profit and revenue forecast on the back of strong sales for its blockbuster cancer drug Keytruda. The New Jersey-based drugmaker said it expected earnings of $8.53 and $8.65 per share, up from its previous forecast of $8.44 to $8.59, and sales of $63.1-$64.3 billion for the year. Merck's new forecast includes a $0.26 per share charge for its $680 million acquisition of cancer drug developer Harpoon Therapeutics, which closed in the first quarter of 2024, the company said.

Reuters 3 hours ago

MRK
+2.09%
Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda

(Reuters) -Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of strong sales for its blockbuster cancer drug Keytruda, sending the company's shares up more than 2% before the bell. Keytruda, the world's top selling drug in 2023, has been Merck's key revenue driver over the past few years and is expected to top $30 billion in sales by 2026 before losing exclusivity toward the end of the decade. The drug is seeing growth from use for additional types of cancers as well as higher patient demand, Chief Financial Officer Caroline Litchfield said.

Reuters 3 hours ago

MRK
+2.09%
Merck Announces First-Quarter 2024 Financial Results

RAHWAY, N.J., April 25, 2024--Merck Announces First-Quarter 2024 Financial Results

Business Wire 3 hours ago

MRK
+2.09%
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales

Merck & Co on Thursday raised its annual profit and revenue forecast on the back of strong sales for its blockbuster cancer drug Keytruda and human papillomavirus (HPV) vaccine Gardasil. The New Jersey-based drugmaker said it expected earnings of $8.53 and $8.65 per share, up from its previous prediction of $8.44 to $8.59, and sales of $63.1-$64.3 billion for the year. Merck's new forecast includes a $0.26 per share charge for its $680 million acquisition of cancer drug developer Harpoon Therapeutics, which closed in the first quarter of 2024, the company said.

Reuters 3 hours ago

MRK
+2.09%
4 Large Drug Stocks to Hold on to Amid Industry Challenges

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.

Zacks yesterday

ABBV

LLY
-1.17%
NVO
Here’s Why Merck & Co. (MRK) Outperformed in Q1

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]

Insider Monkey 2 days ago

MRK
+2.09%
^GSPC
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.

Zacks 2 days ago

MRK
+2.09%
10 Best Performing Biotech ETFs in 2024

In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our detailed introduction to the biotech industry and just want to take a look at some more ETFs, go directly to the 5 Best Performing Biotech ETFs in 2024. Biotechnology is a challenging field, not ideal for […]

Insider Monkey 2 days ago

LLY
-1.17%
EXAS

NBIX
Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 78%

Key Insights Given the large stake in the stock by institutions, Merck's stock price might be vulnerable to their...

Simply Wall St. 4 days ago

MRK
+2.09%
Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. This approval is based on the results from the Phase 3 KEYNOTE-859 trial, whic

CNW Group 6 days ago

MRK
+2.09%
13 Best Low Volatility Stocks to Buy According to Hedge Funds

In this article, we discuss the 13 best low volatility stocks to buy according to hedge funds. To skip the detailed analysis of the current market conditions, go directly to the 5 Best Low Volatility Stocks to Buy According to Hedge Funds. The S&P 500 had a remarkable year in 2023 and the first quarter […]

Insider Monkey 6 days ago

^GSPC

^VIX

TSM
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring

In the biotech and pharmaceutical world, FDA approval is the number one needle mover for drug stocks. Why? Because FDA approval for a drug or treatment can bring years or even decades of steady, high-margin revenue. This is why investors who specifically look to target drug stocks are always aware of an upcoming FDA catalyst for that company. FDA approvals are bullish whether the company is a pre-revenue startup or a global pharmaceutical giant. At the same time, FDA rejections can tank a drug s

InvestorPlace 8 days ago

AMGN
-1.76%
MRK
+2.09%
AQST
Merck Insiders Sold US$15m Of Shares Suggesting Hesitancy

The fact that multiple Merck & Co., Inc. ( NYSE:MRK ) insiders offloaded a considerable amount of shares over the past...

Simply Wall St. 8 days ago

MRK
+2.09%
3 Dow Stocks to Buy Now: Q2 Edition

Let’s be real – the narrative for Dow stocks to buy now tends to be one of relative safety. What are the chances that the 30 companies of the Dow Jones Industrial Average will be the most exciting ideas of any given year? I’d say quite low. However, circumstances can always change, as we’ve seen in the geopolitical environment. Following Iran launching missiles against Israel in retaliation for allegedly bombing its embassy in Syria, the world is on edge regarding Israel’s likely response. What

InvestorPlace 8 days ago

CAT

MRK
+2.09%
CVX
-0.20%
10 Best Low Volatility ETFs To Buy

In this article, we discuss 10 best low volatility ETFs to buy. If you want to skip our discussion on low volatility investments, head over to 5 Best Low Volatility ETFs To Buy. What is Low Volatility Investing? Low volatility investing refers to an investment strategy where a stock portfolio is less volatile in terms […]

Insider Monkey 10 days ago

MSFT

STLAM.MI

MRK
+2.09%
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024

The best biotech stocks to buy are in companies that put a lot of resources into research and development, often with nothing to show for it for years. Regulatory hurdles make finding biotech stocks to buy challenging if you don’t have the patience to wait it out. But when biotech companies win approval to sell and marketing a drug, the potential for profits can be off the charts. That’s why it’s a good idea to at least consider biotech, and whether they have a spot in your portfolio.InvestorPla

InvestorPlace 13 days ago

MRK
+2.09%
NVO

APM
Merck & Co., Inc.'s (NYSE:MRK) Stock Financial Prospects Look Bleak: Should Shareholders Be Prepared For A Share Price Correction?

Merck's (NYSE:MRK) stock is up by 7.0% over the past three months. However, its weak financial performance indicators...

Simply Wall St. 14 days ago

MRK
+2.09%

Performance Overview

Return	MRK	S&P 500
YTD	+19.68%	+5.04%
1-Year	+14.88%	+21.11%
3-Year	+91.37%	+19.86%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Merck & Co., Inc. (MRK)

Meta, IBM sink on earnings, American Airlines and Caterpillar report: Yahoo Finance

Alphabet, Microsoft, Southwest earnings: What to watch

We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt

UPDATE 1-Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda

Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda

Merck Announces First-Quarter 2024 Financial Results

Merck raises 2024 profit forecast on strong cancer, HPV drugs sales

4 Large Drug Stocks to Hold on to Amid Industry Challenges

Here’s Why Merck & Co. (MRK) Outperformed in Q1

How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?

10 Best Performing Biotech ETFs in 2024

Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 78%

Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy

13 Best Low Volatility Stocks to Buy According to Hedge Funds

Coming FDA Approvals Could Send These 3 Drug Stocks Soaring

Merck Insiders Sold US$15m Of Shares Suggesting Hesitancy

3 Dow Stocks to Buy Now: Q2 Edition

10 Best Low Volatility ETFs To Buy

7 A-Rated Aggressive Biotech Stocks to Bet On in 2024

Merck & Co., Inc.'s (NYSE:MRK) Stock Financial Prospects Look Bleak: Should Shareholders Be Prepared For A Share Price Correction?

Performance Overview